查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840604

患者血液管理市场按产品类型、治疗类型、应用和最终用户划分 - 全球预测 2025-2032

Patient Blood Management Market by Product Type, Therapy Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，患者血液管理市场规模将达到 322.2 亿美元，复合年增长率为 8.23%。

主要市场统计数据
基准年 2024 171亿美元
预计年份：2025年 185亿美元
预测年份：2032年 322.2亿美元
复合年增长率 (%) 8.23%

整合实施病人血液管理，明确临床优先事项、保障供应弹性以及运用技术手段，以推动围手术全期安全和机构策略。

病患血液管理正发展成为围手术全期照护、输血医学、供应链管理和以价值为导向的临床结果等多个领域交叉的必要环节。该领域优先考虑最大限度地减少异体血液暴露、优化止血以及根据患者独特的风险状况量身定制治疗性介入。随着医院和专科中心应对日益复杂的手术流程以及对安全性和成本的日益严格审查，患者血液管理实践在临床管治和品质改进议程中变得越来越重要。

临床医生、管理人员和供应链负责人现在从多个角度看待患者血液管理 (PBM)：临床疗效、手术效率和应对血液供应中断的能力。床边凝血监测和自体血液技术的进步使得术中决策更加精准，而止血剂、密封剂和一次性系统的创新则有助于建立更安全的手术通道。这些技术变革，加上不断完善的临床通讯协定（强调术前优化和术后保护），使得 PBM 成为临床和组织层面的双重优先事项。

此外，以病人为中心的照护模式正在重新思考治疗方法方案的沟通和实施方式。围绕着输血阈值、自体血液回收和抗纤溶治疗等方案的共用决策，以及围手术全期优化通讯协定的整合，凸显了医院和专科中心更广泛的文化转变。在此背景下，患者血液管理成为提升临床卓越、运作韧性和改善患者预后的有效途径。

深入分析临床、技术和营运方面的变革，这些变革正在重新定义医疗保健机构中的患者血液管理实践和采购重点。

血液管理格局正受到多种因素的共同影响而再形成，这些因素正在重新定义临床管道和筹资策略。自体输血系统和血液分离设备的成熟，使得自体血液的再利用更加安全，并减少了对外部血液供应的依赖；而新一代凝血监测系统和照护现场技术则支持更快速、更循证的术中干预。这些进步提高了手术全期决策的精细化程度，并增强了即时数据在指导输血实践中的作用。

同时，止血剂、密封系统和局部用药的研发和广泛应用，彻底改变了各专科手术出血的管理方式。改良的配方和给药机制缩短了手术时间，减少了输血需求，并与抗纤溶药物和扩容剂联合使用，支持更保守的输血策略。这些临床进展与按服务付费和基于价值的采购模式的营运趋势相契合，奖励医院展示以结果为导向的药品福利管理（PBM）工具应用。

最后，医疗模式向分散化转型以及门诊手术中心的兴起，迫使製造商和供应商调整产品设计和服务模式，以适应多样化的医疗环境。随着医疗模式逐渐摆脱传统的住院模式，旨在提高速度和便携性的照护现场设备以及一次性解决方案变得日益重要。因此，相关人员必须权衡技术创新与训练、互通性和长期临床证据之间的关係，才能充分发挥这项变革性转变所带来的益处。

深入分析近期关税措施将如何影响患者血液管理生态系统的供应链韧性、筹资策略、製造本地化和临床应用模式。

关税政策的变化可能会对医疗设备和耗材供应链产生连锁反应，进而改变医院、专科中心和经销商的采购成本。关税可能会增加关键零件和成品的进口成本，进而可能提高医疗服务提供者采购自体输液系统、凝血监测仪、止血剂和耗材的成本。这种变化将迫使供应链领导者重新评估其筹资策略，评估总体拥有成本，并优先考虑拥有多元化製造地和本地生产能力的供应商。

除了短期价格影响外，主导调整也将影响供应商的长期策略。製造商可能会加快关键产品的在地化生产，投资区域製造地，或调整产品系列以减少对脆弱供应链的依赖。虽然这些倡议可能在长期内增强韧性，但短期内可能需要资本支出，并影响定价权。对于供应商而言，这将促使他们更加重视采购的弹性。多供应商协议、库存优化以及包含灵活条款的长期采购协议将是缓解市场波动的重要工具。

临床上，除非医疗机构能够明确证明某些技术与改善疗效或提高营运效率之间存在关联，否则较高的设备和耗材成本可能会影响这些技术的普及。因此，用确凿的证据证明其临床和经济价值对于维持技术的普及至关重要。最后，新关税制度引入的法律规范和海关合规复杂性可能会增加行政负担，要求医疗机构投资于合规能力建设，并与供应商更紧密地合作，以简化跨境物流并确保持续获得​​关键的药品福利管理（PBM）产品。

全面的细分洞察揭示了产品类别、治疗方法、临床应用和医疗保健环境如何相互作用，从而影响产品采纳管道和商业化策略。

深入的市场区隔揭示了临床需求、技术契合度和购买行为之间的交集，从而能够针对产品、疗法、应用和终端用户等多个维度製定精准策略。产品类型包括抗纤溶药物、自体输血系统、血液成分分离系统、血液管理抛弃式、凝血监测系统、止血剂和密封剂以及血液容积扩充剂。血液管理抛弃式主要包括细胞清洗试剂套件、收集容器和过滤装置；凝血监测细分市场分为实验室分析仪和照护现场设备；止血剂和密封剂细分市场分为密封剂系统和局部止血剂。每个产品类型都呈现出独特的市场推广路径，其驱动因素包括临床证据、易用性、耗材经济性和与手术全期流程的整合。

治疗方法类型涵盖异体输血、自体输血、细胞回收、止血管理及手术全期手术期血液保护。止血管理领域进一步细分为抗纤溶治疗和局部止血治疗，而手术全期血液保护则包括术中技术、术后护理和术前优化。以治疗为中心的细分揭示了临床方案和多学科团队如何在哪些方面最有效地减少输血暴露并改善预后，其中手术全期优化通常是连接术前评估和术中技术应用的关键环节。

心血管外科手术的临床复杂程度因主动脉手术、冠状动脉绕道手术绕道手术和瓣膜置换术而异，而肿瘤科手术则根据化疗和放疗的具体情况而有所不同。择期手术计画通常着重于术前优化和术中止血管理，创伤照护着重于快速取得照护现场凝血数据和血液成分分离，而肿瘤科手术则需要协调一致的策略来管理复杂治疗方法中的出血风险。

从终端使用者的角度来看，这些设备的应用模式涵盖了门诊手术中心、诊所、医院和专科中心。专科中心可进一步细分为癌症治疗中心、心臟治疗中心和创伤中心。每种医疗环境都有不同的需求，包括设备占地面积、训练强度、耗材物流以及报销敏感度。门诊环境优先考虑紧凑易用且耗材精简的设备，而三级医院和专科中心则需要能够与加护治疗工作流程整合并可扩展以支援大量高风险病例的系统。了解这些细分领域的动态对于产品定位、证据收集以及製定能够引起临床医生和采购相关人员共鸣的商业策略至关重要。

对美洲、中东和非洲以及亚太地区的医疗保健结构、报销模式和法规环境如何推动差异化患者血液管理的普及进行策略性检验。

区域动态影响临床实务模式、采购偏好和监管策略，导致不同地区的医疗服务采纳路径各异。在美洲，医疗保健系统涵盖了大型综合医院网路和数量众多的门诊手术中心，这不仅催生了对高端整合系统的需求，也催生了对携带式照护现场方案的需求。此外，报销模式和私人支付方的影响力也在加速循证药品福利管理（PBM）干预措施的推广应用，因为成本效益数据可以直接指导采购决策。

欧洲、中东和非洲地区监管和报销环境的差异导致了不同的技术采纳曲线。西方医疗体係由于其集中采购和对临床指南的重视，往往倾向于采用有可靠临床数据和长期疗效研究支持的技术。而该地区的新兴市场则以伙伴关係关係为驱动，这些合作关係能够降低成本、提供模组化解决方案、进行本地培训并确保供应的稳定性。监管协调工作和区域采购倡议可能会促进或阻碍市场准入，具体取决于合规性以及认证管道。

在亚太地区，手术量的快速成长和医院基础设施的持续投入，为加速应用病患血液管理（PBM）技术创造了机会。不同的医疗融资模式和医疗服务提供者的能力，正在塑造对可扩展设备、高效抛弃式和经济实惠的止血解决方案的需求。在亚太地区的许多市场，在地化生产和与国内经销商的策略联盟正在优化成本结构，并促进技术的快速应用，尤其是在不断拓展外科和肿瘤治疗的三级医疗中心和专科中心。总而言之，成功的区域策略需要协调当地的监管要求、医疗资金筹措模式和医疗服务提供者的诊疗模式。

权威概述了全球血液管理领域的製造商、利基创新者和区域供应商如何透过临床证据、供应弹性和伙伴关係主导的商业化来竞争。

竞争格局由多元化的全球製造商、专业设备创新者和灵活的区域供应商组成，他们都致力于以临床证据、服务交付和供应链韧性为核心的策略。成熟的设备製造商利用其广泛的产品系列，提供整合解决方案，例如自动化输血系统、凝血监测平台和抛弃式；而规模较小的创新者则通常提供针对特定临床痛点的技术，例如先进的密封剂、一次性过滤系统和快速照护现场分析仪。

企业采取的策略行动包括投资临床证据的产生、拓展分销管道以及与临床中心合作，以实验方式引入新技术。与实际进行证据收集工作的医院和专科中心合作，能够增强企业的价值提案，并有助于将相关成果纳入指南。同时，供应链整合和生产多元化是关键的差异化因素，企业正在探索区域生产基地和多源采购模式，以应对贸易中断和关税变化的影响。

併购和授权授权持续影响企业的能力组合，使企业能够透过耗材和服务来补充其设备产品，从而确保持续的收入来源。同时，企业正着力于培训、远距服务和数位化工具，以提升产品应用率和长期客户维繫。对于买家和合作伙伴而言，关键在于检视供应商在临床效用、整体拥有成本、实证医学证据、支持和供应连续性方面的承诺是否一致。

为实现持久患者血液管理的成功，建议高阶主管和临床领导者采取以下行动，以协调证据产生、供应多样化、定价灵活性和患者特定采用策略。

产业领导者应优先考虑协作方式，将临床证据的产生与适应性供应链策略和商业模式结合，以适应个人化的医疗环境。投资于严谨的临床研究，以证明其能够改善治疗效果和提高手术效率，有助于证明相关设备和治疗方法的合理性，即使在预算紧张的情况下也是如此。同样重要的是，弹性价格设定和合约选项应反映总体拥有成本，使医院能够以有限的前期投资试用新技术。

在营运方面，企业和医疗服务提供者网路应加快推动生产和分销管道多元化，以降低海关和物流风险。在地化生产或与区域製造商建立策略联盟可以减少跨境中断的风险，并在竞争性采购过程中创造成本优势。同时，建立全面的培训计画和远端支援体係可以确保新技术得到安全有效的应用，从而增强临床医生的信心并促进其永续使用。

最后，产品开发与终端用户实际需求的契合至关重要。专为门诊和诊所环境设计的易用型设备和耗材将扩大目标市场，而可扩展至三级医院的模组化系统则能满足专科中心的需求。临床团队、采购部门和供应商客户经理之间的跨职能协作将加速药品福利管理（PBM）实践融入标准诊疗流程，并确保长期价值的实现。

我们透明严谨的调查方法结合了专家访谈、临床指南整合、细分市场映射和检验研讨会，以支持我们的策略洞察，而无需依赖专有的市场量化。

调查方法整合了多个资料流和专家检验，以确保研究结果的可靠性、临床相关性和可操作性。主要资料来源包括对心臟外科、创伤科、肿瘤科和妇产科临床负责人的深度访谈，以及与采购专家、生物医学工程师和医院高级管理人员的讨论，以了解推动技术应用和阻碍技术应用的跨职能观点。这些定性见解与二手文献、临床指南、监管文件和同行评审研究进行三角验证，以检验临床结论和技术性能。

透过对产品、治疗方法、应用和最终用户等维度进行结构化的细分映射，确保分析的严谨性，从而实现对技术适用性和采纳标准的一致性比较。与临床和供应链专家举办的检验研讨会，有助于完善假设并考虑区域差异。透过将製造商的产品规格与实际使用模式进行匹配，并研究能够说明实施挑战和成功因素的用例，进一步增强了资料的完整性。

透过清晰记录专家访谈、采用匿名化通讯协定以及建立可复现的技术和治疗方法分类框架，确保了伦理考量和调查方法的透明度。最终形成的方法论严谨的综合分析，兼顾了定性研究的深度和可交叉验证的证据，为读者提供了战略决策的可靠依据，而无需依赖专有的市场数据。

一项结论性的综合分析证实，整合临床创新、采购灵活性和供应弹性对于在医疗保健环境中充分发挥患者血液管理的潜力至关重要。

患者血液管理不再是辅助性的临床问题，而是手术全期卓越营运、供应链韧性和价值导向医疗的核心组成部分。自体输血、凝血监测、止血剂和抛弃式的进步，使临床医生能够减少对异体输血的依赖，并根据患者的个别风险状况制定个人化的干预措施。同时，采购负责人和製造商必须应对关税相关的压力、供应链重组以及维持技术应用所需的有力临床证据。

展望未来，药品福利管理（PBM）的成功将取决于相关人员能否将临床创新与切实可行的商业和营运策略结合。优先考虑术前优化、投资照护现场能力并建立多学科PBM计画的医院和专科中心将更有利于改善治疗效果并应对资源限制。能够根据不同的医疗环境调整产品设计、注重可靠的循证医学证据并加强本地分销管道的製造商和供应商将能够获得持续的需求并支持长期的临床应用。

最终，对病人安全、结果透明度和稳健供应链的关注将决定药品福利管理（PBM）创新成果能否有效转化为日常临床实践。相关人员，将在品质、安全和设施准备方面看到可衡量的益处。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧演算法应用于预测手术期间个别患者的输血需求
  • 引入照护现场血红蛋白和血液凝固检验，以指导即时输血决策并减少异体输血的使用。
  • 引入自体血液回收和术中自体输血技术，以最大限度地减少大型手术期间的输血量
  • 监管和报销奖励推动了综合性患者血液管理认证计画的出现
  • 扩大产科和创伤科患者血液管理通讯协定，以控制出血并改善孕产妇结局
  • 在各种医疗环境中利用远端医疗平台进行术前贫血评估和输血后监测
  • 铁缺乏症的筛检和管理日益被认为是实证医学的基础组成部分。
  • 加强多学科团队间的协作，以实施限制性输血阈值和强化病患安全措施
  • 整合真实世界证据和卫生经济学分析，以证明病患血液管理的成本节约和临床效益。
  • 医院正越来越多地采用由预测分析和决策支援系统支援的、针对特定患者的输血演算法。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的患者血液管理市场

  • 抗纤溶药物
  • 自体输血系统
  • 血液成分分离系统
  • 血液管理耗材
    • 细胞清洗套件
    • 血液收集池
    • 过滤装置
  • 凝血监测系统
    • 实验室分析设备
    • 照护现场设备
  • 止血剂和密封剂
    • 密封系统
    • 局部止血剂
  • 膨鬆剂

9. 按治疗类型分類的患者血液管理市场

  • 异体输血
  • 自体输血
  • 细胞拯救
  • 止血管理
    • 抗纤溶治疗
    • 局部止血疗法
  • 手术全期血液保护
    • 术中技术
    • 术后护理
    • 术前优化

第十章 病人血液管理市场：依应用划分

  • 心血管外科
    • 主动脉手术
    • 冠状动脉绕道手术手术
    • 瓣膜置换手术
  • 择期手术
  • 产科
  • 肿瘤治疗
    • 化疗
    • 放射线治疗
  • 创伤

第十一章 以最终用户分類的病患血液管理市场

  • 门诊手术中心
  • 诊所
  • 医院
  • 专业中心
    • 癌症治疗中心
    • 心臟护理中心
    • 创伤中心

12. 按地区分類的患者血液管理市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 集团病患血液管理市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国患者血液管理市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Haemonetics Corporation
    • Fresenius Kabi AG
    • Grifols, SA
    • Terumo Corporation
    • Baxter International Inc.
    • Roche Diagnostics International AG
    • Octapharma AG
    • CSL Limited
    • ZOLL Medical Corporation
    • Macopharma SA
Product Code: MRR-0372549B1FF1

The Patient Blood Management Market is projected to grow by USD 32.22 billion at a CAGR of 8.23% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.10 billion
Estimated Year [2025] USD 18.50 billion
Forecast Year [2032] USD 32.22 billion
CAGR (%) 8.23%

An integrative introduction to patient blood management that frames clinical priorities, supply resilience, and technological enablers driving perioperative safety and institutional strategy

Patient blood management is evolving into a cross-disciplinary imperative that intersects perioperative care, transfusion medicine, supply chain stewardship, and value-driven clinical outcomes. The field prioritizes minimizing exposure to allogeneic blood, optimizing hemostasis, and aligning therapeutic interventions with patient-specific risk profiles. As hospitals and specialty centers navigate growing procedural complexity and heightened scrutiny over safety and costs, PBM practices are increasingly central to clinical governance and quality improvement agendas.

Clinicians, administrators, and supply chain leaders now view PBM through multiple lenses: clinical efficacy, procedural efficiency, and resilience against disruptions to blood availability. Advances in point-of-care coagulation monitoring and autologous technologies enable more precise intraoperative decision-making, while innovations in hemostats, sealants, and disposable systems support safer surgical pathways. These technological shifts are complemented by evolving clinical protocols that emphasize preoperative optimization and postoperative conservation, making PBM both a clinical and organizational priority.

Moreover, patient-centric care models are reframing how therapeutic choices are communicated and implemented. Shared decision-making around transfusion thresholds, alternatives such as cell salvage or antifibrinolytic therapy, and the integration of perioperative optimization protocols underscore a broader cultural shift in hospitals and specialty centers. In this context, PBM becomes an instrument for clinical excellence, operational resilience, and measurable improvements in patient outcomes.

A detailed analysis of the transformative clinical, technological, and operational shifts redefining patient blood management practices and procurement priorities across care settings

The landscape of blood management is being reshaped by multiple converging forces that redefine clinical pathways and procurement strategies. Technological maturation in autotransfusion systems and blood component separation devices enables safer reuse of autologous blood and reduces dependency on external supply, while next-generation coagulation monitoring systems and point-of-care diagnostics support faster, evidence-based intraoperative interventions. These advances increase the granularity of perioperative decision-making and elevate the role of real-time data in guiding transfusion practices.

Simultaneously, the development and wider adoption of hemostats, sealant systems, and topical agents have transformed how surgical bleeding is managed across specialties. Improved formulations and delivery mechanisms reduce surgical time and transfusion needs, and when combined with antifibrinolytic agents and volume expanders, they support more conservative transfusion strategies. This clinical evolution dovetails with operational trends toward bundled payments and value-based procurement, incentivizing hospitals to demonstrate outcomes-driven use of PBM tools.

Finally, the strategic shift toward decentralized care and growth of ambulatory surgical centers is prompting manufacturers and suppliers to adapt product design and service models for varied care settings. Point-of-care devices engineered for speed and portability, alongside disposable-focused solutions, are increasingly relevant as care migrates out of traditional inpatient environments. As a result, stakeholders must balance innovation adoption with training, interoperability, and long-term clinical evidence to fully realize the benefits of these transformative shifts.

An in-depth exploration of how recent tariff actions affect supply chain resilience, procurement strategy, manufacturing localization, and clinical adoption patterns across the patient blood management ecosystem

Changes in tariff policy can reverberate across the supply chain for medical devices and consumables, altering procurement calculus for hospitals, specialty centers, and distributors. When tariffs increase import costs for key components or finished devices, healthcare providers may encounter higher acquisition costs for autotransfusion systems, coagulation monitors, hemostats, and disposables. This shift compels supply chain leaders to reassess sourcing strategies, evaluate total cost of ownership, and prioritize suppliers with diversified manufacturing footprints or localized production capabilities.

Beyond immediate pricing effects, tariff-driven adjustments influence long-term supplier strategies. Manufacturers may accelerate localization of critical production, invest in regional manufacturing hubs, or modify product portfolios to reduce exposure to vulnerable supply corridors. Such moves can improve resilience over time but may require near-term capital expenditure that affects pricing dynamics. For providers, the consequence is a renewed emphasis on procurement agility: multi-supplier contracting, inventory optimization, and longer-term purchasing agreements with flexibility clauses become important tools to mitigate volatility.

Clinically, higher device or disposable costs could influence adoption curves for certain technologies unless providers can clearly link them to improved outcomes or operational efficiencies. Therefore, demonstrating clinical and economic value through robust evidence becomes essential to sustain adoption. Finally, regulatory oversight and customs compliance complexities introduced by new tariff regimes can increase administrative burden, encouraging healthcare organizations to invest in compliance capabilities and to partner more closely with suppliers to streamline cross-border logistics and maintain uninterrupted access to critical PBM products.

Comprehensive segmentation insights revealing how product classes, therapeutic approaches, clinical applications, and care settings interact to shape adoption pathways and commercialization strategies

Insightful segmentation illuminates where clinical need, technology fit, and purchasing behavior intersect, enabling targeted strategies across product, therapy, application, and end-user dimensions. Based on product type, the landscape includes antifibrinolytics, autotransfusion systems, blood component separation systems, blood management disposables, coagulation monitoring systems, hemostats and sealants, and volume expanders; within blood management disposables the focus extends to cell washing kits, collection reservoirs, and filtration devices, while coagulation monitoring is distinguished by laboratory analyzers and point-of-care devices and hemostats and sealants break down into sealant systems and topical hemostats. Each product category follows its own adoption arc, driven by clinical evidence, ease of use, consumable economics, and integration with perioperative workflows.

Considering therapy type, the framework spans allogeneic transfusion, autologous transfusion, cell salvage, hemostasis management, and perioperative blood conservation; the hemostasis management domain further divides into antifibrinolytic therapy and topical hemostats therapy, and perioperative blood conservation encompasses intraoperative techniques, postoperative care, and preoperative optimization. Therapy-focused segmentation reveals where clinical protocols and multidisciplinary teams can most effectively reduce transfusion exposure and improve outcomes, with perioperative optimization often serving as the nexus between preoperative assessment and intraoperative technology utilization.

Application-based segmentation highlights cardiovascular surgery, elective surgery, obstetrics, oncology treatments, and trauma; within cardiovascular surgery the clinical complexity varies across aortic surgery, coronary artery bypass grafting, and valve replacement procedures, while oncology treatments are differentiated by chemotherapy and radiotherapy contexts. These clinical settings dictate distinct PBM priorities: elective surgery programs often emphasize preoperative optimization and intraoperative hemostatic control, trauma care stresses rapid access to point-of-care coagulation data and blood component separation, and oncology care requires coordinated strategies to manage bleeding risk during complex treatment regimens.

From an end-user perspective, adoption patterns span ambulatory surgical centers, clinics, hospitals, and specialty centers; specialty centers are further categorized into cancer treatment centers, cardiac care centers, and trauma centers. Each care setting imposes different requirements for device footprint, training intensity, consumable logistics, and reimbursement sensitivity. Ambulatory environments prioritize compact, easy-to-use devices with streamlined disposables, whereas tertiary hospitals and specialty centers demand scalable systems that can integrate with intensive care workflows and support high-volume, high-acuity cases. Understanding these segmentation dynamics is essential for product positioning, evidence generation, and tailored commercial strategies that resonate with clinicians and procurement stakeholders alike.

A strategic examination of how regional healthcare structures, reimbursement models, and regulatory environments in the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated patient blood management adoption

Regional dynamics influence clinical practice patterns, procurement preferences, and regulatory navigation, producing distinct pathways to adoption across major geographies. In the Americas, healthcare systems vary from large integrated hospital networks to a proliferation of ambulatory surgical centers, creating demand for both high-end integrated systems and portable point-of-care solutions; reimbursement paradigms and private payer influences also accelerate adoption of evidence-backed PBM interventions in settings where cost-effectiveness data can be translated directly into procurement decisions.

In Europe, Middle East & Africa, a diverse regulatory and reimbursement landscape leads to differentiated adoption curves. Western European health systems with centralized procurement and strong emphasis on clinical guidelines often favor technologies backed by robust clinical data and long-term outcome studies, while emerging markets in the region are driven by affordability, modular solutions, and partnerships that enable local training and supply resilience. Regulatory harmonization efforts and regional procurement initiatives can both enable and constrain market entry depending on compliance alignment and certification pathways.

Across Asia-Pacific, rapid expansion of procedural volumes and ongoing investments in hospital infrastructure create opportunities for accelerated adoption of PBM technologies. Variations in healthcare financing and provider capabilities shape demand for scalable devices, consumable-efficient disposables, and cost-effective hemostatic solutions. In many markets across the region, localization of manufacturing and strategic partnerships with domestic distributors optimize cost structures and facilitate faster implementation, particularly in tertiary and specialty centers that are expanding surgical and oncology services. Overall, regional strategies must reconcile local regulatory requirements, healthcare financing models, and provider practice patterns to succeed.

An authoritative overview of how global manufacturers, niche innovators, and regional suppliers compete through clinical evidence, supply resilience, and partnership-driven commercialization in blood management

The competitive landscape is composed of diversified global manufacturers, specialized device innovators, and nimble regional suppliers, each pursuing strategies that emphasize clinical evidence, service delivery, and supply resilience. Established device companies leverage broad product portfolios to offer integrated solutions that bundle autotransfusion systems, coagulation monitoring platforms, and disposables, while smaller innovators often target specific clinical pain points with focused technologies such as advanced sealants, single-use filtration systems, or rapid point-of-care analyzers.

Strategic behaviors among companies include investment in clinical evidence generation, expansion of distribution channels, and collaborative arrangements with clinical centers to pilot new technologies. Partnerships with hospitals and specialty centers for real-world evidence collection strengthen value propositions and facilitate guideline inclusion. Meanwhile, supply chain integration and manufacturing diversification are important differentiators, with companies seeking regional production sites or multi-sourcing models to limit exposure to trade disruptions and tariff shifts.

Mergers, acquisitions, and licensing arrangements continue to shape capability portfolios, enabling companies to complement device offerings with consumables and services that drive recurring revenue streams. At the same time, corporate emphasis on training, remote servicing, and digital tools enhances product adoption and long-term customer retention. For purchasers and partners, the critical lens is alignment between clinical utility, total cost of ownership, and vendor commitments to evidence, support, and supply continuity.

Actionable recommendations for executives and clinical leaders to align evidence generation, supply diversification, pricing flexibility, and tailored adoption strategies for durable patient blood management success

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation with adaptive supply chain strategies and commercial models tailored to distinct care settings. Investing in rigorous clinical studies that demonstrate improvements in outcomes and procedural efficiency will help justify adoption of devices and therapies even in environments with constrained budgets. Equally important is the creation of flexible pricing and contracting options that reflect total cost of ownership and enable hospitals to trial technologies with limited upfront commitment.

Operationally, companies and provider networks should accelerate efforts to diversify manufacturing and distribution to mitigate tariff and logistics risks. Localization of production or strategic partnerships with regional manufacturers can lower exposure to cross-border disruptions and create cost advantages in competitive procurement processes. In parallel, building comprehensive training programs and remote-support ecosystems ensures that new technologies are implemented safely and effectively, driving clinician confidence and sustainable utilization.

Finally, aligning product development with end-user realities is paramount. Devices and disposables designed for ease of use in ambulatory and clinic environments will expand addressable markets, while modular systems that can scale for tertiary hospitals will meet demands of specialty centers. Cross-functional collaboration between clinical teams, procurement, and supplier account management will accelerate integration of PBM practices into standard care pathways and secure long-term value realization.

A transparent and rigorous research methodology combining expert interviews, clinical guideline synthesis, segmentation mapping, and validation workshops to underpin strategic insights without relying on proprietary market quantification

The research approach integrates multiple data streams and expert validation to ensure findings are robust, clinically relevant, and operationally actionable. Primary inputs include in-depth interviews with clinical leaders across cardiac surgery, trauma, oncology, and obstetrics, as well as discussions with procurement specialists, biomedical engineers, and senior hospital administrators to capture cross-functional perspectives on adoption drivers and barriers. These qualitative insights are triangulated with secondary literature, clinical guidelines, regulatory documents, and peer-reviewed studies to validate clinical assertions and technology performance.

Analytical rigor is maintained through structured segmentation mapping across product, therapy, application, and end-user dimensions, enabling consistent comparison of technology fit and adoption criteria. Validation workshops with clinical experts and supply chain professionals help refine assumptions and contextualize regional nuances. Data integrity is further strengthened by reconciling manufacturer product specifications with real-world usage patterns and by reviewing case studies that illustrate implementation challenges and success factors.

Ethical considerations and methodological transparency are upheld through clear documentation of inclusion criteria for expert interviews, anonymization protocols, and a replicable framework for categorizing technologies and therapies. The result is a methodologically sound synthesis that balances qualitative depth with cross-referenced evidence, equipping readers with a defensible basis for strategic decisions without relying on proprietary market quantifications.

A conclusive synthesis affirming that integrating clinical innovation, procurement agility, and supply resilience is essential to realize the full potential of patient blood management across care environments

Synthesis of the preceding insights underscores a clear strategic imperative: patient blood management is no longer an ancillary clinical concern but a core component of perioperative excellence, supply chain resilience, and value-based care. Advancements in autotransfusion, coagulation monitoring, hemostatic agents, and disposables are enabling clinicians to reduce reliance on allogeneic transfusion and to tailor interventions to individual patient risk profiles. At the same time, procurement leaders and manufacturers must navigate tariff-related pressures, supply chain realignment, and the need for compelling clinical evidence to sustain adoption.

Looking ahead, success in PBM will hinge on the ability of stakeholders to integrate clinical innovation with pragmatic commercial and operational strategies. Hospitals and specialty centers that prioritize preoperative optimization, invest in point-of-care capabilities, and foster multidisciplinary PBM programs will be better positioned to improve outcomes and manage resource constraints. Manufacturers and suppliers that align product design with diverse care settings, commit to robust evidence generation, and strengthen regional supply channels will capture enduring demand and support long-term clinical adoption.

Ultimately, the collective focus on patient safety, outcome transparency, and resilient supply chains will determine how effectively PBM innovations translate into routine clinical practice. Stakeholders that act decisively to bridge clinical priorities with procurement flexibility and operational preparedness will create measurable advantages in quality, safety, and institutional readiness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms in predicting individual patient transfusion requirements during surgery
  • 5.2. Adoption of point-of-care hemoglobin and coagulation testing to guide real-time transfusion decisions and reduce allogeneic blood use
  • 5.3. Implementation of cell salvage and intraoperative autotransfusion techniques to minimize donor blood transfusion in major surgeries
  • 5.4. Emergence of comprehensive patient blood management accreditation programs driven by regulatory and reimbursement incentives
  • 5.5. Expansion of patient blood management protocols in obstetrics and trauma to address hemorrhage management and improve maternal outcomes
  • 5.6. Utilization of telehealth platforms for preoperative anemia assessment and post-transfusion monitoring in diverse healthcare settings
  • 5.7. Growing emphasis on iron deficiency screening and management as a foundational component of evidence-based patient blood management
  • 5.8. Increasing collaboration between multidisciplinary teams to implement restrictive transfusion thresholds and enhanced patient safety measures
  • 5.9. Integration of real-world evidence and health economics analyses to demonstrate cost savings and clinical benefits of patient blood management
  • 5.10. Rising adoption of patient-tailored transfusion algorithms supported by predictive analytics and decision support systems in hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient Blood Management Market, by Product Type

  • 8.1. Antifibrinolytics
  • 8.2. Autotransfusion Systems
  • 8.3. Blood Component Separation Systems
  • 8.4. Blood Management Disposables
    • 8.4.1. Cell Washing Kits
    • 8.4.2. Collection Reservoirs
    • 8.4.3. Filtration Devices
  • 8.5. Coagulation Monitoring Systems
    • 8.5.1. Laboratory Analyzers
    • 8.5.2. Point Of Care Devices
  • 8.6. Hemostats And Sealants
    • 8.6.1. Sealant Systems
    • 8.6.2. Topical Hemostats
  • 8.7. Volume Expanders

9. Patient Blood Management Market, by Therapy Type

  • 9.1. Allogeneic Transfusion
  • 9.2. Autologous Transfusion
  • 9.3. Cell Salvage
  • 9.4. Hemostasis Management
    • 9.4.1. Antifibrinolytic Therapy
    • 9.4.2. Topical Hemostats Therapy
  • 9.5. Perioperative Blood Conservation
    • 9.5.1. Intraoperative Techniques
    • 9.5.2. Postoperative Care
    • 9.5.3. Preoperative Optimization

10. Patient Blood Management Market, by Application

  • 10.1. Cardiovascular Surgery
    • 10.1.1. Aortic Surgery
    • 10.1.2. Coronary Artery Bypass Grafting
    • 10.1.3. Valve Replacement Procedures
  • 10.2. Elective Surgery
  • 10.3. Obstetrics
  • 10.4. Oncology Treatments
    • 10.4.1. Chemotherapy
    • 10.4.2. Radiotherapy
  • 10.5. Trauma

11. Patient Blood Management Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Specialty Centers
    • 11.4.1. Cancer Treatment Centers
    • 11.4.2. Cardiac Care Centers
    • 11.4.3. Trauma Centers

12. Patient Blood Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Patient Blood Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Patient Blood Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Haemonetics Corporation
    • 15.3.2. Fresenius Kabi AG
    • 15.3.3. Grifols, S.A.
    • 15.3.4. Terumo Corporation
    • 15.3.5. Baxter International Inc.
    • 15.3.6. Roche Diagnostics International AG
    • 15.3.7. Octapharma AG
    • 15.3.8. CSL Limited
    • 15.3.9. ZOLL Medical Corporation
    • 15.3.10. Macopharma SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PATIENT BLOOD MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PATIENT BLOOD MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PATIENT BLOOD MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS PATIENT